News Search Results
Jan 14, 2026, 10:30 ET Pharmaceutical Filtration Consumables Market worth $18.03 billion by 2030 | MarketsandMarkets™
(Sweden).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 14, 2026, 09:00 ET Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion
focused on veterinary biologics, pet nutrition, and animal wellness.At UCLA, Yuyu Venture Studio has spun off two subsidiaries. Yuyu Bio is a biotechnology company developing feline-specific biologics for chronic and underserved conditions, while Mervyn's Petcare is a cat-only health supplement company
More news about: Yuyu Pharma
Jan 14, 2026, 09:00 ET L.E.K. Consulting Announces Seven Promotions to Partner
transaction support across the agribusiness value chain. Garrigues has deep expertise in crop inputs, produce, food ingredients and industrial biotechnology. He holds an A.B. in biomechanical engineering from Harvard University and a Ph.D. in biomedical engineering from Duke University.
More news about: L.E.K. Consulting
Jan 14, 2026, 07:00 ET GitGuardian Closes 2025 with Strong Enterprise Momentum, Protecting Millions of Developers Worldwide
technology-enabled mobility and delivery platform with 30,000+ employees worldwide headquartered in the USAA global pharmaceutical and biotechnology company with 90,000+ employees, headquartered in EuropeA major enterprise software vendor with 110,000+ employeesLeading financial
More news about: GitGuardian
Jan 13, 2026, 19:01 ET ElpasBio and Fosun Kairos Announce Commercialization Collaboration for AlloJoin® Stem Cell Therapy
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced that it has entered into a collaboration agreement with Fosun Kairos for the commercialization
More news about: ElpasBio Holdings
Jan 13, 2026, 18:46 ET Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
www.lottebiologics.com About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell
More news about: LOTTE BIOLOGICS
Jan 13, 2026, 18:00 ET Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
requirements and ensuring stable supply for customers worldwide.About Rakuten Medical, Inc.Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell
More news about: Rakuten Medical, Inc.
Jan 13, 2026, 12:36 ET FRIDAY DEADLINE: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026
CLICK HERE.Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.The complaint alleges that, throughout the Class Period, Defendants
More news about: Berger Montague
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs, 89 clinical programs, and 6 approved products. The Adimab technology has been transferred
More news about: Adimab, LLC
Jan 13, 2026, 10:30 ET Predictive Clinical Biomarkers Market worth $14.69 billion by 2030 | MarketsandMarkets™
(US).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 13, 2026, 10:01 ET Algae-Based Biofuel Market to Reach USD 19.16 Billion by 2032 as Sustainable Aviation Fuel and Energy Security Redefine the Global Fuel Mix
offer drop-in compatibility with existing engines and infrastructure, making them commercially viable transition fuels.Advances in biotechnology and cultivation efficiency are improving economics. Progress in photobioreactor design, strain optimization, and downstream processing is steadily
More news about: DataM Intelligence 4 Market Research LLP
Jan 13, 2026, 09:59 ET Beacon Global Strategies Launches Export Control and Industrial Strategy Practice, Names Meghan Harris Managing Director and Adds Kevin Kurland as Senior Advisor
U.S. manufacturing and diversifying supply chains creates business opportunity across critical technology sectors—including AI, semiconductors, biotechnology, robotics, critical minerals, and energy. This industrial reinvigoration brings renewed attention to the regulatory frameworks needed to manage
More news about: Beacon Global Strategies
Jan 13, 2026, 09:30 ET The Mark Foundation for Cancer Research Announces 2026 Emerging Leader Awards, Committing $3.75 Million to Next-Generation Oncology Breakthroughs
scientists. This support has proven to be a powerful catalyst, with past awards supporting the launch of new clinical trials, the formation of innovative biotechnology companies, and fundamental shifts in our understanding of cancer's driving mechanisms.This year, The Mark Foundation is proud to partner
More news about: The Mark Foundation for Cancer Research
Jan 13, 2026, 09:16 ET Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
MONTREAL, Jan. 13, 2026 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and
More news about: Thryv Therapeutics Inc.
Jan 13, 2026, 09:10 ET Biokin to Present at J.P. Morgan's 44th Annual Healthcare Conference
REDMOND, Wash., Jan. 13, 2026 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced that its affiliate, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin) will present at the J.P. Morgan's 44th
More news about: SystImmune, Inc.
Jan 13, 2026, 09:03 ET Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation
Genesys Capital, will join Enspire's Board of Directors."Genesys Capital invests in companies developing transformative therapies across biotechnology, pharmaceuticals, and medical technology," said Stiff. "The Enspire team has made remarkable progress advancing DBS-enabled rehabilitation for patients
More news about: Enspire DBS Therapy, Inc.
Jan 13, 2026, 08:44 ET Applied Cells and Immuneel Therapeutics Announce Strategic Collaboration to Advance Truly Affordable CAR-T Cell Therapies in India and Globally
manufacturing while maintaining the highest quality standards. About Immuneel Therapeutics Immuneel Therapeutics is a clinical-stage biotechnology company developing affordable, best-in-class cell and gene therapies, with a focus on CAR-T therapies for cancer patients in India and emerging
More news about: Applied Cells
Jan 13, 2026, 08:15 ET Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
properties and manufacturability at early commercial scale.About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Jan 13, 2026, 08:05 ET Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada
neurology, psychiatry, pediatrics, rare diseases, hematology, cardiology and neuromuscular disorders. Kye partners with global pharmaceutical and biotechnology companies to license and launch medicines that matter, and deliver better outcomes to our partners, Canadian healthcare professionals, and most
More news about: Kye Pharmaceuticals Inc.
Jan 13, 2026, 07:47 ET Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Jan. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Jan 13, 2026, 07:42 ET Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Jan 13, 2026, 07:07 ET Leo International Group Relocates Global Headquarters to Singapore Ahead of Its Centennial
integration of six majority-owned portfolio companies on 17 December 2025. These entities span AI diagnostics, biomedical research, immunology, biotechnology and clinical care delivery across Asia-Pacific and the United States. Together, they form an AI-driven precision health platform designed to connect
More news about: Leo International Group
Jan 13, 2026, 07:00 ET Magnet Biomedicine Expands Leadership with Appointment of Nick Vlahakis, M.B.B.S., as Chief Medical Officer
target and tissue specificity, and offer the convenience of oral delivery.About Magnet BiomedicineMagnet Biomedicine is a biotechnology company pioneering the systematic design and development of precision-engineered induced proximity therapeutics. The company's TrueGlue™ discovery
More news about: Magnet Biomedicine
Jan 13, 2026, 07:00 ET Synthego Announces Entry into Molecular Biology and Clinical Diagnostic Reagents Market
pressing research and therapeutic needs, ever-advancing developments in human health.About SynthegoSynthego is a pioneering biotechnology company specializing in synthetic biology and genome engineering. Dedicated to providing scientists with the tools, expertise, and support needed
More news about: Synthego
Jan 13, 2026, 03:26 ET Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based
More news about: Immunofoco Biotechnology